All semaglutide articles
-
OpinionCompounding problems
Regulating the line between a vital service and grey-market profiteering is a mess
-
BusinessWeight-loss drug shortages prompt copycats and counterfeits
Novo Nordisk and Eli Lilly have struggled to meet huge demand for new hormone mimic obesity treatments